Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Both nilotinib and dasatinib were superior to standard imatinib therapy in patients with newly diagnosed CML.

Nilotinib (Tasigna) and dasatinib (Sprycel) are second-generation tyrosine kinase inhibitors that are approved for second-line treatment of patients with chronic myeloid leukemia (CML) who are intolerant of, or resistant to, the first-generation inhibitor imatinib. To assess the efficacy and safety of nilotinib and dasatinib as initial treatments for patients with newly diagnosed, chronic-phase CML, investigators conducted two industry-supported, multicenter phase III trials in which the agents were compared with standard imatinib therapy.

In the nilotinib study, 846 patients were randomized to receive one of three treatments: lower-dose nilotinib (300 mg orally twice daily), higher-dose nilotinib (400 mg orally twice daily), or imatinib (40…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee